Please login to the form below

Not currently logged in
Email:
Password:

monoclonal antibodies

This page shows the latest monoclonal antibodies news and features for those working in and with pharma, biotech and healthcare.

New centre aims to Catapult UK into cell and gene therapy lead

New centre aims to Catapult UK into cell and gene therapy lead

Keith Thompson (pictured right), chief executive of the government-funded Cell and Gene Therapy Catapult, says the most obvious example of this was monoclonal antibodies, which the UK played a lead

Latest news

  • Novartis plans major expansion of French antibody facility Novartis plans major expansion of French antibody facility

    Set up in 2005, the site in Huningue is already one of the world's largest production facilities for monoclonal antibodies from mammalian cells, manufacturing antibodies used in marketed asthma, ... inflammatory and anti-rejection drugs, as well as

  • Immunotherapy and future directions in oncology Immunotherapy and future directions in oncology

    It is the ability to identify a suitable target antigen, and then design and reliably manufacture antibodies with high specificity for the target molecule, that made monoclonal antibodies such useful tools ... Antibody-drug conjugates are complex

  • Baxalta inks $1.6bn immuno-oncology deal with Symphogen Baxalta inks $1.6bn immuno-oncology deal with Symphogen

    The identity of the mechanisms targeted in the Baxalta/Symphogen alliance have not been divulged, but the Danish company focuses on the development of mixed monoclonal antibodies (MAbs) that address multiple

  • Amgen and Allergan close on Avastin biosimilar filing Amgen and Allergan close on Avastin biosimilar filing

    ABP 215 is one of nine biosimilars, including four antibodies for cancer, that are being developed by Amgen and Allergan under an alliance originally started in 2011. ... While biosimilars for first-generation protein drugs have been available in Europe

  • BMS’ Opdivo wins anti-PD1 race in Europe BMS’ Opdivo wins anti-PD1 race in Europe

    In the last three years, the authorisation of targeted treatments, including monoclonal antibodies, BRAF V600 and MEK inhibitors, have significantly changed the therapeutic landscape.

More from news
Approximately 2 fully matching, plus 78 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • The tipping point The tipping point

    For example, since 2015, when the first monoclonal antibody biosimilar, infliximab, was launched in Europe we have seen a notable increase in the overall use of infliximab. ... For example, providing therapeutic drug monitoring (TDM) to minimise loss of

  • What makes the difference in the biosimilar battle? What makes the difference in the biosimilar battle?

    Taking the example of multiple blockbuster monoclonal antibodies close to their patent expiry dates, we can see that numerous big pharma companies like Merck, Amgen and Pfizer and even smaller to

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... The other two companies, the Swedish company, BioInvent, and the British company, Abzena, have

  • Deal Watch April 2016 Deal Watch April 2016

    1, 200. ZymeWorks (US). GSK (UK). License and option. Preclinical bi-specific antibodies based on Azymetric platform for treatment of solid tumours. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Brewis joins from GlaxoSmithKline where he served as vice president and head head of biopharmaceutical research, leading a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and

  • V Bryan Lawlis joins board of KaloBios V Bryan Lawlis joins board of KaloBios

    patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios. ... This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics